Written by Targeted Sequencing Market Overview
The global targeted sequencing market is estimated to reach $10,976.1 million in 2032, reveals the premium market intelligence study. The study also highlights that the market is set to witness a CAGR of 13.12% during the forecast period 2022-2032.
Growth in the global targeted sequencing market is driven by the growing adoption of targeted sequencing solutions in clinical applications at all levels.
USP of the Report
• The vast segmentation of the report, especially the vast number of applications considered
• It is one of the first reports focusing completely on targeted sequencing present currently in the market
• The workflow of all types and methods of targeted sequencing is explained in detail to understand the market scenario better
• Product specifications and comparative analysis
• Competitive benchmarking of key players for each software and consulting service type
• A detailed comparison between targeted sequencing and whole genome sequencing
Analyst Perspective
According to Nitish Kumar, Lead Analyst of the report, “Global targeted sequencing market is a rapidly emerging market and is expected to dominate NGS sequencing in the coming years due to the continuous increase in the demand for disease diagnosis and industrial analysis using next-generation sequencing technology.”
Key Companies Operating in The Market
The key players in the global targeted sequencing market have been analyzed and profiled in the study, consisting of both product-based and service-based companies, as well as a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the global targeted sequencing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
The key players profiled in the report include Agilent Technologies, Inc., Azenta US, Inc. (GENEWIZ), BGI Group (MGI Tech Co., Ltd.), CD Genomics, Daicel Corporation (Daicel Arbor Biosciences), Danaher. (Integrated DNA Technologies, Inc.), F. Hoffmann-La Roche Ltd, Illumina, Inc., LGC Limited (LGC Biosearch Technologies), PacBio., PerkinElmer Inc., Psomagen, QIAGEN N.V., Takara Bio Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., and Twist Bioscience.
Key Questions Answered in the Report/h3>
• How is the targeted sequencing market revolutionizing the NGS sequencing industry?
• What are the major market drivers, challenges, and opportunities in the global targeted sequencing market?
• What are the underlying structures resulting in the emerging trends within the targeted sequencing market?
• How did the COVID-19 pandemic impact the global targeted sequencing market?
• What are the key development strategies that are being implemented by major players to sustain themselves in the market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of targeted sequencing applications?
• What are the potential entry barriers that are expected to be faced by the companies willing to enter a particular region in the market?
• What will be the growth rate of the global targeted sequencing market during the forecast period 2022-2032?
• What are the growth opportunities for the targeted sequencing companies in the region of their operation?
• Who are the leading players with significant offerings in the global targeted sequencing market?
• Which companies are anticipated to be highly disruptive in the future and why?